Latest Thrombotic microangiopathy Stories
- Phase 2 Clinical Trial in aHUS and Other TMAs Expected to Begin Next Quarter - SEATTLE, March 10, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive
-- Successful Phase 1 Results Set the Stage for Trials in Patients with Life-Threatening Blood Disorders -- SEATTLE, March 4, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER)
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.